Scienture Holdings, Inc.

Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium